BridgeBio Pharma BBIO Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's investing cash flow?
- BridgeBio Pharma (BBIO) reported investing cash flow of -$42.74M in Q1 2026.
- How has BridgeBio Pharma's investing cash flow changed year-over-year?
- BridgeBio Pharma's investing cash flow decreased by 2579.3% year-over-year, from -$1.6M to -$42.74M.
- What is the long-term trend for BridgeBio Pharma's investing cash flow?
- Over 2 years (2022 to 2024), BridgeBio Pharma's investing cash flow has grown at a -62.4% compound annual growth rate (CAGR), from $453.15M to $64.02M.
- What does investing cash flow mean?
- The net cash flow from buying and selling long-term assets and investments.
- How do you interpret investing cash flow?
- Negative values typically indicate active investment in growth or treasury assets, while positive values may indicate divestment or liquidation.
- How does investing cash flow compare across companies?
- Reflects the company's stage of growth; early-stage firms often show negative investing cash flows.